Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Prostate Cancer treatment details. Biologic therapy. Chemotherapy. Institut Jean-Godinot, Reims, France

Survival: 19.3 months
Toxicity Grade: 5
Treatments: Biologic therapy
Country: France
City/State/Province: Reims
Hospital: Institut Jean-Godinot
Journal: Link
Date: 6/2007

Patients: This phase II study involved 92 patients with advanced hormone-refractory prostate cancer. The men had received a hormone-based therapy before entering this study, but had no prior treatment with any chemotherapy. The age range was 46.2 to 86.3 years.

Treatment: The patients were treated with chemotherapy drugs, one of which also has effects on hormones (estramustine). Docetaxel and estramustine were given to 47 patients, and 44 patients were treated with docetaxel only.

Toxicity: One patient died from causes possibly related to treatment. Within 30 days of the last treatment, 4 other patients also died, but the causes of death were not attributed to the drugs used in the study. Febrile neutropenia occurred in one patient from each treatment group. Grade 3 and 4 toxicities occurred in 15% of patients receiving docetaxel and estramustine, and in 16% of those treated with docetaxel. These toxicities included neutropenia, anemia, infection, stomatitis, and pulmonary edema.

Results: The median overall survival was 19.3 months for patients treated with docetaxel and estramustine and was 17.8 months for those treated with only docetaxel.

Support: This study was supported by Sanofi-Aventis, which developed and markets docetaxel as Taxotere.

Correspondence: Dr. J-C Eymard

E-mail to a Friend Email Physician More Information